Literature DB >> 29105276

Quadriceps muscle fat infiltration is associated with cardiometabolic risk in COPD.

Isabelle Vivodtzev1, Luc Moncharmont2, Renaud Tamisier1, Jean-Christian Borel1, François Arbib3, Bernard Wuyam1, Patrick Lévy1, François Maltais4, Gilbert Ferretti2, Jean-Louis Pépin1.   

Abstract

PURPOSE: Losses of peripheral muscle mass and ectopic fat accumulation have been associated with cardiometabolic morbidity in COPD. We aimed at identifying the relationship between quadriceps muscle fat infiltration and cardiovascular risk.
MATERIALS AND METHODS: From 2009 to 2014, 78 COPD patients (64 ± 8 years; 80% male) were prospectively included after having given written consent (ethical committee approval number: 2006-A00491-50). The cohort was divided into three groups (tertiles) according to body mass index (BMI), low [15 < BMI≤23·3], middle [23·3 < BMI≤27·6] and high [27·6 < BMI≤36] kg/m²). Measurements were respiratory function, plasmatic biomarkers and surrogate markers of cardiovascular risk (arterial stiffness and endothelial function). Mid-thigh quadriceps muscle volume and per cent of muscle fat infiltration, as assessed by 64-slice CT scanning, were compared between the tertiles. ANOVA or Kruskal-Wallis tests were used for statistical analyses with Bonferroni's correction for the 'post hoc' tests.
RESULTS: Intramuscular fat volume was 52% [95% CI, 43 to 60%] of total quadriceps volume in high BMI vs. 47% [38 to 55%] and 34% [29 to 38%] in the middle and low-BMI groups, respectively (P<0·0001), without differences between groups in fat-free muscle volumes. Elevated muscle fat infiltration correlated with lower thiol to protein ratios in the whole population reflecting impaired antioxidant capacity (r = 0·50; P = 0·009). Furthermore, muscle fat infiltration was linked to endothelial dysfunction (r = -0·49, P = 0·01) in the low-BMI group.
CONCLUSION: Skeletal muscle fat infiltration may be an indicator of increased cardiometabolic risk in both obese and lean COPD patients.
© 2017 Scandinavian Society of Clinical Physiology and Nuclear Medicine. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CT-scan; antioxidant capacities; cardiovascular risk; endothelial dysfunction

Mesh:

Substances:

Year:  2017        PMID: 29105276     DOI: 10.1111/cpf.12481

Source DB:  PubMed          Journal:  Clin Physiol Funct Imaging        ISSN: 1475-0961            Impact factor:   2.273


  5 in total

1.  Static one-leg standing balance test as a screening tool for low muscle mass in healthy elderly women.

Authors:  Praval Khanal; Lingxiao He; Georgina K Stebbings; Gladys L Onambele-Pearson; Hans Degens; Alun G Williams; Martine Thomis; Christopher I Morse
Journal:  Aging Clin Exp Res       Date:  2021-03-13       Impact factor: 3.636

2.  Skeletal Myosteatosis is Associated with Systemic Inflammation and a Loss of Muscle Bioenergetics in Stable COPD.

Authors:  Hans Lennart Persson; Apostolos Sioutas; Magnus Kentson; Petra Jacobson; Peter Lundberg; Olof Dahlqvist Leinhard; Mikael Fredrik Forsgren
Journal:  J Inflamm Res       Date:  2022-08-01

3.  Single-cell RNA sequencing and lipidomics reveal cell and lipid dynamics of fat infiltration in skeletal muscle.

Authors:  Ziye Xu; Wenjing You; Wentao Chen; Yanbing Zhou; Qiuyun Nong; Teresa G Valencak; Yizhen Wang; Tizhong Shan
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-11-27       Impact factor: 12.910

Review 4.  Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review.

Authors:  Chun-Wei Li; Kang Yu; Ng Shyh-Chang; Zongmin Jiang; Taoyan Liu; Shilin Ma; Lanfang Luo; Lu Guang; Kun Liang; Wenwu Ma; Hefan Miao; Wenhua Cao; Ruirui Liu; Ling-Juan Jiang; Song-Lin Yu; Chao Li; Hui-Jun Liu; Long-Yu Xu; Rong-Ji Liu; Xin-Yuan Zhang; Gao-Shan Liu
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-02-02       Impact factor: 12.910

5.  Total Antioxidant Status in Stable Chronic Obstructive Pulmonary Disease.

Authors:  Marina Hlavati; Svetlana Tomić; Krunoslav Buljan; Vikica Buljanović; Ivan Feldi; Silva Butković-Soldo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-10-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.